INS and gestational diabetes: In a recent study, between 2015 and 2018 in the USA, insulin (26 to 44%) followed by metformin (17 to 29%) has replaced glyburide (58 to 27%) as the most common pharmacotherapy for GDM among a privately insured US population during a time of evolving professional guidelines (196).